The Alzheimer’s disease market is expected to grow at a CAGR of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the 8MM ...

Effectively treating and preventing this common form of dementia will require a cocktail of drugs and a combination of ...

Plus: A startup bioengineering off-the-shelf arteries, how viruses may cause Alzheimer’s, water-powered satellites and more.

The study reveals a potential link between concussions and the activation of dormant viruses, which may lead to ...

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

New research suggests that concussions and repetitive head trauma may reactivate dormant viruses like HSV-1 in the brain, potentially triggering neurodegenerative diseases such as Alzheimer’s.

Inflammation in the brain can reawaken dormant viruses, which may lead to the onset of neurodegenerative disease, a new study ...

The New Brunswick, N.J., pharmaceutical giant said posdinemab has shown potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid from treated Alzheimer's patients, and in ...

Roche Holding, Novartis, and Eli Lilly & Company Dominate the Competitive Landscape Global Central Nervous System ...

Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow ...

Researchers uncover mechanisms that may connect the dots between trauma events and the emergence of disease. They point to ...